Research and Markets: Pulmonary Hypertension - Global Market Research 2015-2019 - Increased Focus on Combination Therapies

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/l9zbnb/pulmonary) has announced the addition of the "Pulmonary Hypertension - Global Market Research 2015-2019" report to their offering.

The global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

The report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

The hypertension treatment is shifting toward the use of combination therapies that employ two or more drugs. Combination therapy with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure at a faster pace, help in obtaining target blood pressure, and decrease adverse effects. The treatment is also aimed at targeting various disease mechanisms that may result in better outcomes.

According to the report, the median survival for a person living with pulmonary hypertension is only five to six years. In addition, the current treatments do not target the underlying cause of the disorder. Thus, the disorder treatment is associated with poor patient compliance. Hence, patients often discontinue the treatment without completing the treatment cycle. Other classes (or types) of medications used to treat pulmonary hypertension also have side effects. Therefore, current treatment options result in unmet medical needs that warrant the development of new drugs with better safety and efficacy, thereby driving the market.

Further, the report states that patent expiry of drugs such as Revatio is hindering the market growth by allowing low-cost generics to enter the market. Poor patient compliance during treatment due to the adverse effects of the drugs used is also impeding the market growth.

Key vendors

- Actelion

- Bayer

- GlaxoSmithKline

- United Therapeutics

Other prominent vendors

- Aires Pharmaceuticals

- Arena Pharmaceuticals

- Bial

- DEKA

- Dong-A ST

- Gilead

- Merck

- Northern Therapeutics

- Novartis

- Pfizer

- PhaseBio

For more information visit http://www.researchandmarkets.com/research/l9zbnb/pulmonary

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals